Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover, proof-of-mechanism study investigating the effect of miglustat on the nasal potential difference in adult patients with cystic fibrosis homozygous for the F508del mutation

Trial Profile

Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover, proof-of-mechanism study investigating the effect of miglustat on the nasal potential difference in adult patients with cystic fibrosis homozygous for the F508del mutation

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Miglustat (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacodynamics
  • Acronyms MIGLUSTAT-CF
  • Most Recent Events

    • 31 Jul 2016 Planned End Date changed from 1 Aug 2017 to 1 Jan 2018.
    • 31 Jul 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
    • 20 Apr 2015 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top